# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Matt O'Brien maintains TransMedics Gr (NASDAQ:TMDX) with a Overweight and maintains $120 price tar...
TD Cowen analyst Joshua Jennings maintains TransMedics Gr (NASDAQ:TMDX) with a Buy and raises the price target from $130 to ...
Strong data from TransMedics' clinical trials is expected to drive adoption. Longer-term, the annual market opportunity is ...
Stephens & Co. analyst George Sellers initiates coverage on TransMedics Gr (NASDAQ:TMDX) with a Overweight rating and an...